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Abstract
Background
Complications of diverticular disease are increasingly common, possibly linked to increasing
obesity. Visceral fat could contribute to the development of symptomatic diverticular disease
through its pro-inflammatory effects.
Objective
The study had 2 aims. A) to develop a semi-automated algorithm to measure abdominal adi-
pose tissue from 2-echo magnetic resonance imaging (MRI) data; B) to use this to deter-
mine if visceral fat was associated with bowel symptoms and inflammatory markers in
patients with symptomatic and asymptomatic diverticular disease.
Design
An observational study measuring visceral fat using MRI together with serum adiponectin,
leptin, stool calprotectin and patient-reported somatisation and bowel habit.
Setting
Medical and imaging research centres of a university hospital.
Participants
MRI scans were performed on 55 patients after an overnight fast measuring abdominal sub-
cutaneous and visceral adipose tissue volumes together with small bowel water content
(SBWC). Blood and stool samples were collected and patients kept a 2 week stool diary and
completed a somatisation questionnaire.
PLOS ONE | https://doi.org/10.1371/journal.pone.0216528 May 8, 2019 1 / 15
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Murray KA, Hoad CL, Garratt J, Kaviani M,
Marciani L, Smith JK, et al. (2019) A pilot study of
visceral fat and its association with adipokines,
stool calprotectin and symptoms in patients with
diverticulosis. PLoS ONE 14(5): e0216528. https://
doi.org/10.1371/journal.pone.0216528
Editor: John Green, University Hospital Llandough,
UNITED KINGDOM
Received: September 10, 2018
Accepted: April 18, 2019
Published: May 8, 2019
Copyright: © 2019 Murray et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the manuscript and its Supporting
Information files.
Funding: We are grateful for the infrastructure and
financial support from the NIHR Nottingham
Digestive Diseases Biomedical Research Unit
(Grant BRU 2011-2022). The views expressed here
are those of the authors and not necessarily those
of the NHS, the NIHR or the Department of Health.
Competing interests: The authors have declared
that no competing interests exist.
Main outcome measures
Difference in the volume of visceral fat between symptomatic and asymptomatic patients.
Results
There were no significant differences in visceral (p = 0.98) or subcutaneous adipose (p =
0.60) tissue between symptomatic and asymptomatic patients. However measured fat vol-
umes were associated with serum adipokines. Adiponectin showed an inverse correlation
with visceral adipose tissue (VAT) (Spearman ρ = -0.5, p = 0.0003), which correlated nega-
tively with SBWC (ρ = -0.3, p = 0.05). Leptin correlated positively with subcutaneous adipose
tissue (ρ = 0.8, p < 0.0001). Overweight patients (BMI > 25 kgm-2) showed a moderate cor-
relation between calprotectin and VAT (ρ = 0.3, p = 0.05). Somatization scores were signifi-
cantly higher in symptomatic patients (p < 0.0003).
Conclusions
Increasing visceral fat is associated with lower serum adiponectin and increased faecal cal-
protectin suggesting a pro-inflammatory effect which may predispose to the development of
complications of diverticulosis.
Introduction
Diverticulosis is a common feature of ageing in the developed world with an incidence which
increases with each decade, reaching >50% by the eighth decade and 60% in the ninth [1].
Most patients have asymptomatic diverticulosis, but around 20% develop symptomatic diver-
ticular disease [2]. Studies indicate that hospital admissions for diverticular disease, as well as
the incidence of complications and operative interventions are increasing [1, 3, 4], creating a
growing disease burden in terms of cost, morbidity and mortality [5].
Early reports of post-mortem examinations [6] suggested 50% of colons from diverticular
disease patients had excess fatty tissue compared to 25% of control samples. More recently,
long term cohort studies have identified obesity as one of the strongest risk factors for develop-
ing symptomatic diverticular disease. According to a Swedish study over a 28-year follow-up
period [7], BMI� 30 kg m-2 increased the relative risk of of being hospitalised with symptom-
atic diverticular disease by 4.4. Another study of male health care professionals over an 18 year
follow-up period [8] identified that subjects with a BMI� 30 kg m-2 had a significantly
increased relative risk (RR) of developing diverticulitis (RR = 1.8) or diverticular bleeding
(RR = 3.2) compared to those with BMI < 21 kg m-2. Obesity has been linked to an increased
risk of perforated diverticular disease compared to controls using data from the UK General
Practice Research Database (GPRD), RR = 1.4 [9].
While BMI gives a rough measure of total body fat, it is becoming increasingly apparent
that visceral fat is much more metabolically active than subcutaneous fat and also a more
important predictor of metabolic and intestinal complications such as diverticulitis [10] and
Crohn’s disease [2]. Macrophage infiltration into adipose tissue is known to accompany obe-
sity and such macrophages show signs of activation. This leads to the development of an
inflammatory state [11], that is shown to decrease when weight is lost. While the link between
macrophages in adipose tissue and the morbidities associated with obesity is unclear, several
authors have hypothesised that it is specifically macrophage infiltration into intra-abdominal
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but not subcutaneous fat [12] that is associated with the metabolic syndrome [13, 14]. It has
been further hypothesized that visceral fat is not just a storage organ but an important endo-
crine organ which plays a key role in metabolism [15] leading to metabolic disorders by the
release of pro-inflammatory adipokines and cytokines such as adiponectin and leptin. Leptin
is pro-inflammatory, stimulating monocytes and macrophages to secrete pro-inflammatory
cytokines, nitric oxide and prostaglandins while adiponectin seems mainly anti-inflammatory
[16]. The specific role of mesenteric fat in the development of symptomatic colonic diverticu-
lar disease has not however yet been explored.
With the increased interest in quantifying abdominal fat, magnetic resonance imaging
(MRI) has become the modality of choice for many research studies as it is a non-ionising,
multi-planar imaging technique, allowing repeated measurements of adipose tissue distribu-
tion across the abdomen [17]. However there is no consensus as to the best method of image
acquisition or image segmentation, with many different pulse sequences and image processing
algorithms suggested across the literature [17–27]. Semi-automatic and automatic algorithms
have been proposed to reduce the observer measurement time and hence make more global
estimates of VAT and subcutaneous adipose tissue (SAT) possible.
We have recently developed MRI techniques to non-invasively study the small bowel [28]
and colon in health and disease [29]. We have shown a reduction in small bowel water content
and accelerated transit in irritable bowel syndrome patients with diarrhoea (IBS-D) compared
to healthy controls, both fasting and postprandially [30]. This reduction may reflect increased
tone of the small bowel wall. Whether similar effects could be present in symptomatic divertic-
ular patients in whom the predominant bowel pattern is now recognised to be diarrhoea [31]
and whether adipokines can exacerbate these symptoms remains to be demonstrated.
This project had two aims; firstly to develop a semi-automated algorithm to measure
abdominal subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT) and total adipose
tissue (TAT) from 2-echo MRI data. Our second aim was to use this algorithm to investigate
the correlations between visceral and subcutaneous adipose tissue and adipokines in symp-
tomatic and asymptomatic diverticular disease and also to assess small bowel water to deter-
mine if it was linked to bowel pattern in these patients.
Materials and methods
The protocol (S1 Protocol) was reviewed and approved by Derby Research Ethics Committee
(approval number 10/H0405/80). The study was carried out according to Good Clinical Prac-
tice and registered on Clinicaltrials.gov identifier NCT02278770. All patients gave written
informed consent.
Study participants
58 patients were recruited from gastrointestinal medicine and surgery clinics in Nottingham.
Two were not scanned and one failed to complete the 2 week bowel questionnaire leaving 55
patients (24 male; aged 63 ± 10 years with body mass index (BMI) 29.3 ± 5.4 kg m-2) who com-
pleted the study (Fig 1). Eligibility criteria included patients with a diagnosis for diverticular
disease confirmed on endoscopy, barium enema or CT scan and no other gastrointestinal dis-
orders, aged between 18 and 85 years old. Patients were consecutively recruited without any
additional selection criteria apart from excluding those on long term non-steroidal anti-
inflammatory agents (NSAIDs). Patients were considered symptomatic if they reported lower
abdominal pain on 3 or more days/month for more than 3 months, a cut-off paralleling the
threshold set by the Rome III Committee for the frequency of symptoms to meet criteria for
Irritable Bowel Syndrome[32]. This threshold excludes 94% of the normal population. We felt
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that this was a reasonable distinction between symptomatic and asymptomatic patients [33].
The presence of multiple somatic symptoms were assessed using Patient Health Questionnaire
12-Somatic Symptom (PHQ12-SS) score, previously shown to be elevated in patients with
symptomatic diverticular disease [34]. Scores� 7 were considered high. The Hospital Anxiety
and Depression Scale (HADS) questionnaire was also administered at screening in an effort to
assess the contribution of anxiety and depression which are known to influence self-reported
symptoms[35]. All patients were further screened with a MRI safety screening questionnaire.
Out of the 55 patients who completed the study, 10 (6 male, mean age 65 yrs, range 53–73 yrs)
were selected based on BMI by someone blind to whether they were symptomatic or asymp-
tomatic, to provide a wide range of BMIs (23–38 kg m-2) to facilitate the development of the
semi-automated algorithm.
Study design
Patients were required to make one visit to the study centre, prior to which they were asked to
complete a 14-day diary recording the presence of pain, daily bowel habit and Bristol Stool
Form score for each bowel movement. They also collected a frozen or freshly passed stool sam-
ple for analysis of faecal calprotectin, which they brought to the study centre on the day of
their MRI visit. They were asked to cease taking laxatives for 24 hours and antispasmodics for
Fig 1. CONSORT flow diagram for the study. The CONSORT checklist can be found in S1 Checklist in the
Supporting Information.
https://doi.org/10.1371/journal.pone.0216528.g001
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12 hours prior to scanning. Participants attended the study centre after a 12 hour overnight
fast. On arrival, blood samples were taken to assess leptin and adiponectin levels as well as
baseline pulse, blood pressure, height and weight measurements. They were then scanned over
a period of 10 minutes which completed the study.
Magnetic resonance imaging (MRI) protocol. Patients were scanned using a 1.5T,
whole-body scanner (Achieva, Philips Medical System, The Netherlands). All participants
were positioned supine in the scanner with a 16 element SENSE (sensitivity encoding) receive
torso coil around the abdomen. The volumes of subcutaneous and visceral fat were measured
using a 3D T1 weighted mDIXON (Modified DIXON) protocol [36] which acquired in-phase,
out-of-phase, water only and fat only images in the transverse plane. This acquired 150 slices
in 3 stacks; each 50 slice stack acquired in a 13 second breath hold (flip angle = 15o, SENSE =
2.0, TE1 = 1.8 ms, TE2 = 4 ms, TR = 5.4 ms, acquired resolution 1.5 x 1.95 x 6 mm
3, recon-
structed resolution 1.25 x 1.25 x 3 mm3). The volume of freely mobile water in the small
bowel (small bowel water content, SBWC) was measured using a single short turbo spin echo
sequence, which acquired 24 slices with a single 24 second expiration breath hold (TR = 8000
ms, TE = 320 ms, 512 x 512 reconstructed matrix, voxel size 0.78 x 0.78 x 7 mm3). This method
has been previously described and validated [28].
Laboratory analyses. Faecal calprotectin was analysed using a commercially available
ELISA kit (Bu¨hlmann Laboratories AG, Scho¨nenbuch, Switzerland). Adiponectin (sBios-
ciences, Frankfurt, Germany) and leptin (R&D Systems, MN, USA) in blood samples were
both analysed by ELISA, according to manufacturers’ protocols.
Data analysis. Volumes of abdominal fat were determined using a semi-automatic algo-
rithm written in IDL 6.4 (Research Systems, Boulder Co, USA) (described fully in S1 Methods
Supporting Information, which includes all validation studies of the algorithm). The pro-
gramme uses prior positional knowledge without training data to segment visceral (VAT),
subcutaneous (SAT), total adipose tissue (TAT) and abdominal volume in MRI data. The
operator first defines the L4/L5 intervertebral disc and selects 25 slices (each slice 3 mm thick)
above and below this disc to form a 51-slice region of interest. This region forms the total body
mask, and provides volume data for the abdominal volume. A threshold level is set for the fat-
only data to generate a fat mask within the total body mask, which was used to differentiate
between VAT and SAT. Final volumes of VAT, SAT and abdomen were calculated from the
data from the central 30 slices only. As part of the validation process of the algorithm, a subset
of 10 datasets were used to compare the fat regions defined by the semi-automatic algorithm
with the ‘gold standard’ manual segmentation. SBWC was measured using previously
described methods [28].
Power and statistical analysis. No previous studies have used MRI measures of VAT and
SAT to assess its relationship to symptoms of diverticular disease. However, based on results of
Liou who used abdominal MRI to detect fat distribution and found mean abdominal fat vol-
ume of 3829 (1106) [37], the sample size required to detect a 30% difference in VAT between
groups with a power of 80% and p< 0.05 is 16 participants per group. We recruited 17 asymp-
tomatic subjects but recruited a larger number of symptomatic patients to improve our power
to detect associations between the different variables assessed.
Statistical analyses were carried out using Prism 6 (GraphPad Software Inc., San Diego,
CA). Comparisons between groups were performed using 2 –tailed unpaired t-tests and corre-
lations were tested using Spearman’s ρ. Normally distributed data were reported as mean (SD)
while median (IQR) was used to report non-normally distributed data.
For the algorithm validation study, a Bland-Altman analysis was used to determine the Bias
and 95% Confidence Intervals between the manual and semi-automatic fat volumes. The dice
coefficient was used to determine the accuracy of each of the regions defined.
Visceral fat and diverticulosis
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Results
Of the 55 patients consented, 17 had no pain (labelled asymptomatic) and 38 experienced
chronic abdominal pain (labelled symptomatic). There were also 7 participants who recorded
an attack of diverticulitis in the preceding year. Clinical details are provided in Table 1.
29 of the 38 symptomatic patients had an abnormally elevated somatization score
(PHQ12-SS)� 7. The somatization score (PHQ-12 SS) was associated with both the number
of days with pain (Spearman ρ = 0.6, P < 0.0001) and number of hours / day with pain (Spear-
man ρ = 0.5, P <0.0003). Increasing BMI was also associated with loose stools (Spearman ρ =
0.3, P = 0.02).
MRI results
All 55 patients tolerated the non-invasive procedure well and visceral and subcutaneous fat
were easily identified using the mDIXON protocol. Diverticula could also be seen predomi-
nantly in the sigmoid region, with some visible in the descending colon (Fig 2).
Fat measurements. As expected, BMI showed a strong, significant correlation with VAT
(Spearman ρ = 0.7, P< 0.0001), SAT (Spearman ρ = 0.7, P< 0.0001) and TAT (Spearman ρ =
0.9, P< 0.0001). BMI also correlated strongly with the abdominal volume of patients (Spear-
man ρ = 0.9, P < 0.0001). There were however no significant differences between asymptom-
atic and symptomatic patients with respect to BMI (mean difference [95% CI] 0.5 [-2.3–3.4] kg
m-2 P = 0.70), nor median volumes of VAT (median difference [95% CI] 39 [-347.5–319.2]
mL, P = 0.98), SAT (median difference [95% CI] 67.4 [-391.2–718.9] mL, P = 0.60) and TAT
(median difference [95% CI] 422.9 [-586.1–900.1] mL, P = 0.82).
Adiponectin, leptin and faecal calprotectin
Neither adiponectin nor leptin or calprotectin were significantly different between symptom-
atic and asymptomatic patients (Table 2). However, patients with calprotectin higher than
50 μg g-1 had a lower concentration of plasma adiponectin (median difference [95% CI] 1.45
[0.19–2.69] μg g-1, P = 0.02), and a higher volume of VAT, median difference [95% CI] 251.4
Table 1. Characteristics of symptomatic and asymptomatic patients with diverticulosisa.
Symptomatic Asymptomatic Pb
Age (years) 64 (54–70) 66 (57–69) 0.7
Gender
% Female 60.5 47.1
% Male 39.5 52.9
BMI (kg m-2) 29.0 (4.7) 28.3 (4.9) 0.7
Number of hours/day with pain (hours) 1.2 (0.6–2.9) 0 0.0001
Stool frequency (bowel movements/week) 1.7 (1.3–2.1) 1.6 (1.4–2.4) 1.0
PHQ-12 SS 9.0 (6.8–11.0) 4.0 (2.0–7.5) 0.0003
HAD score
Anxiety 6.0 ± 4.2 4.2 ± 3.3 0.14
Depression 3.5 (1.8–6.0) 2.0 (1.0–3.5) 0.09
Laxative use 2 2
Diverticulitis in the last year 6 1 0.42
a Normally distributed data are shown as mean (SD) while median (IQR) is used for non-normally distributed data
b P values are calculated using unpaired t tests for normally distributed data and Mann-Whitney tests when non-normal
https://doi.org/10.1371/journal.pone.0216528.t001
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[-16.6–626.7] mL, P = 0.06 compared to those with normal calprotectin. BMI (P = 0.45),
abdominal volumes (P = 0.26) and leptin concentrations (P = 0.43) were not significantly differ-
ent. Calprotectin levels of the 7 patients with an attack of diverticulitis in the previous year were
not significantly different from those with no such history (median (IQR) 49 (34–193) μg g-1).
Correlations between adipokines, calprotectin and visceral and subcutaneous fat. Cor-
relations between adipokines, calprotectin and adipose tissue are shown in Fig 3. This figure
shows strong negative correlations between adiponectin and fat, while leptin is shown to corre-
late strongly with SAT and TAT, but less strongly with VAT.
The median faecal calprotectin concentration was 46.3 (27–100) μg g-1, 46% being above
the upper limit of normal in our laboratory of 50 μg g-1. While there were no correlations
between calprotectin and fat for the full dataset of patients, for the overweight subgroup a
post-hoc analysis showed there were modest correlations between calprotectin and VAT
(Spearman ρ = 0.3, P = 0.05), BMI (Spearman ρ = 0.3, P = 0.04) and abdominal volume (Spear-
man ρ = 0.4, P = 0.01).
Correlation of objective markers with bowel habit and pain frequency. Average stool
form ranged from 1.9–6 and this measure was shown to correlate positively with BMI and neg-
atively with adiponectin (Table 3). BMI also correlated positively with the number of days with
loose stool and negatively with adiponectin. Calprotectin correlated negatively with adiponec-
tin. All other correlations are shown in Table 3.
Small bowel water content (SBWC). Fasting SBWC was not significantly different
between symptomatic and asymptomatic patients being mean (SD) 72.0 (79.5) mL and 66.7
(40.5) mL respectively. SBWC was however found to correlate negatively with VAT (Spearman
ρ = -0.3, P = 0.05), SAT (Spearman ρ = -0.4, P = 0.006, TAT (Spearman ρ = -0.4, P = 0.003),
Fig 2. Fat only mDIXON image of the abdominal region of a patient with diverticular disease. The portion of the
colon with the diverticula is highlighted in the boxed image. The image was collected using a T1 weighted, water
suppressed, sequence where adipose tissue appears bright and allows for its quantification. The colon and other organs
appear darkly coloured, providing a contrast for visualisation of the diverticula.
https://doi.org/10.1371/journal.pone.0216528.g002
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leptin (Spearman ρ = -0.4, P = 0.002) and BMI (Spearman ρ = -0.3, P = 0.04). There were no
significant differences between patients with BMI< 25 kgm-2 and those with BMI� 25 kgm-2
mean difference 7 (26), 95% CI [–46–60] mL, P = 0.40.
Validation of the fat segmentation algorithm. Comparison of the volumes from 10
diverticular disease patients measured using the semi-automatic algorithm and manual seg-
mentation are given in Table 4. A broad range of volumes were measured across the subjects
for the different adipose tissue regions. The dice coefficients for all the different regions were
greater than 0.95, showing excellent agreement between the boundaries defined by the algo-
rithm and those defined by the ‘gold standard’ manual segmentation.
Discussion
In this study of adults with diverticular disease, we developed a semi-automated algorithm to
measure abdominal adipose tissue from MRI data and used it to determine if visceral adipose
tissue was associated with bowel symptoms and inflammatory markers in patients with symp-
tomatic and asymptomatic diverticular disease. There were no significant differences in adi-
pose tissue volume between symptomatic and asymptomatic patients, but there were some
associations noted between adipose tissue volumes, stool calprotectin and serum adipokines.
We report here that in overweight diverticular disease subjects, increasing VAT is associ-
ated with an increase in gut inflammation as assessed by faecal calprotectin. Faecal calprotec-
tin; a S100A 8/9 heterodimer found in the cytosol of neutrophils and macrophages [38], is
widely used to assess gut inflammation. Our data is further evidence that increasing visceral fat
is pro-inflammatory and may play a role in the association between obesity and the complica-
tions of diverticular disease. A recent report examining visceral fat obtained from patients
undergoing gastric bypass surgery for morbid obesity, has shown that calprotectin is generated
by activated macrophages in visceral adipose tissue, possibly under the influence of TNF alpha
[39]. Its correlation with visceral obesity in our overweight patients supports the idea that
increased VAT may enhance the inflammatory response in diverticular disease which could
predispose to bacterial translocation and microabscess formation or visceral hypersensitivity.
We have previously shown that these are linked to increased mucosal expression of a range
of pro-inflammatory mediators including TNFα, IL6, monocyte chemotactic peptide 1
(MCP1) and prostaglandin E (PGE) in diverticular disease [40]. Others have also reported a
link between faecal calprotectin, mucosal lymphocyte count and symptoms in diverticular dis-
ease, implying low grade inflammation could cause pain and bowel disturbance [41]. One of
the strongest predictors of the development of pain in diverticulosis is prior diverticulitis. Dur-
ing this inflammation, the gut barrier is breached and bacteria enter the visceral fat, which in
experimental colitis can be shown to act as second layer of defence [42]. This inflammatory
state may well persist even after the original mucosal injury has healed and could contribute to
the increased risk of symptomatic diverticular disease associated with obesity [43]. The associ-
ation between calprotectin and VAT could also be indirect since a high fat diet is associated
both with obesity and increased gut permeability [44]. It should be noted that we did not
restrict the patients diet as the only clinical trials of diet have failed to show that red meat alters
faecal calprotectin [45].
Table 2. Adipokines in symptomatic and asymptomatic patients. Data are shown as median (IQR).
Symptomatic Asymptomatic P
Adiponectin (μg ml-1) 4.2 (3.0–6.8) 3.9 (2.5–6.2) 0.8
Leptin (ng mL-1) 14.6 (5.9–32.5) 10.79 (4.2–18.9) 0.2
Calprotectin (μg ml-1) 44.6 (26.7–116.3) 46.3 (23.6–68.2) 0.6
https://doi.org/10.1371/journal.pone.0216528.t002
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Fig 3. Correlations between adipokines and measures of adipose tissue. Some of the stronger correlations between leptin, adiponectin and MRI
measures of fat volume. � = P<0.05, �� = P<0.005, ��� = P<0.001.
https://doi.org/10.1371/journal.pone.0216528.g003
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Adiponectin was found to correlate negatively with VAT, TAT, abdominal volume, BMI
and calprotectin. This is in keeping with past studies, where concentration of adiponectin
decreases in obesity but increases when weight is lost [46]. Indeed, adiponectin release from
the omentum of women undergoing hysterectomy has been negatively correlated with the
amount of visceral fat, while release from SAT was not associated with any metabolic abnor-
malities [47]. The negative correlation of adiponectin with calprotectin is in keeping with the
anti-inflammatory nature of adiponectin, reduction of which in obesity, may contribute to a
pro-inflammatory state.
Unlike adiponectin, concentrations of leptin were very strongly correlated with SAT, TAT
and abdominal volume, while correlations with VAT were only modest. Leptin mRNA is
expressed at a greater rate in SAT than it is in VAT, possibly due to the differences in VAT and
SAT cell sizes [48], and this is in keeping with what was seen for our patients. Leptin was also
inversely correlated with SBWC, which in turn was inversely correlated with SAT, TAT and
BMI.
This finding of a negative correlation between SBWC and adiposity together with the link
between BMI and loose stools is in keeping with epidemiological data which links diarrhoea
with increased BMI [49] and our own data, showing reduced small bowel water in irritable
bowel syndrome patients with diarrhoea [50]. The underlying mechanism is unclear and
requires further study, but leptin has been reported to increase transit by altering the sensitivity
to CCK, which accelerates distal small intestinal transit [51]. Faster transit could lead to the
reduced water in the small bowel we have observed.
Table 3. Association between bowel symptoms and objective measures of adiposity, adipokines and calprotectin.
Spearman ρ P
Average Bristol Stool Form Score
BMI 0.4 0.005
Adiponectin -0.3 0.0095
VAT 0.3 0.03
Number of days/ week hard stool
VAT -0.3 0.03
VAT/SAT -0.4 0.004
Adiponectin 0.5 0.0002
Adiponectin
BMI -0.4 0.0008
Calprotectin -0.4 0.009
https://doi.org/10.1371/journal.pone.0216528.t003
Table 4. Comparison of manual and semi-automatic definitions of adipose tissue regions (N = 10) obtained across 30 slices.
VOLUMES (ml) RATIOS
VAT SAT TAT VAT/SAT VAT/TAT
Mean Semi-Auto Data 1020±310 2540±1180 3660±1350 0.46±0.19 0.29±0.08
Range 620–1490 1000–5230 2030–6690 0.20–0.85 0.16–0.42
Mean Manual Data 1020±320 2540±1170 3660±1350 0.46±0.19 0.29±0.08
Range 600–1500 1000–5230 2030–6690 0.20–0.86 0.16–0.42
B-A Bias (MAN-AUTO) -0.2 -27.8 0.0 0.004 -0.001
B-A 95%CI -25.2 to 24.8 -62.4 to 6.8 -0.2 to 0.2 -0.008to 0.016 -0.009 to 0.007
Mean Dice Co-efficient 0.983±0.009 0.994±0.002 1.000±0.000 N/A N/A
https://doi.org/10.1371/journal.pone.0216528.t004
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We found increased VAT, which represents the more metabolically active fat, was linked to
frequent soft stools. This agrees with Lee et al., [52] who report that visceral obesity is associ-
ated with an increased risk of IBS-D.
Recent reports have highlighted the link between obesity and complications of diverticular
disease [4]. Obesity is clearly linked to the risk of type II diabetes and the metabolic syndrome,
thought to be mediated via the production of pro-inflammatory cytokines by visceral fat. Our
study attempted to determine possible mechanisms underlying the epidemiological data linking
obesity with inflammatory complications of diverticular disease. We confirmed, using our
improved imaging methods, that serum levels of leptin are closely correlated with total body fat,
and that this correlation is greater than for VAT which only accounts for a fraction of total body
fat. In contrast serum adiponectin, an anti-inflammatory adipokine derived from visceral fat, cor-
relates more strongly negatively with more metabolically active VAT than with total abdominal fat.
Our method is patient acceptable though limited by patient size, a study weakness which is
being corrected by the large bore scanners now becoming available which make scanning very
obese patients feasible. Future work should focus on the effect of weight loss on markers of gut
inflammation which would show whether the relationship we have observed is causal or a spu-
rious association mediated by diet or changes in microbiota.
This should be regarded as a pilot study since the numbers were small and only included a
few patients with previous diverticulitis. It is clinically important to distinguish between recur-
rent acute diverticulitis (where the pain comes in episodes lasting several days separated by
long periods of no symptoms) and IBS-like diverticular disease where the pain is often daily
and short lived. A future study comparing larger numbers of both groups is needed to clarify
whether visceral fat is linked to symptoms in either of these 2 groups.
One of the strengths of this study was the use of MRI which allowed the collection of multi-
ple slices through the abdomen [53], which has been shown to improve the accuracy of visceral
adipose tissue measurements. Our semi-automated programme analysed a larger cross sec-
tional area centred at the L4/L5 intervertebral disc without the use of large amounts of training
data or complicated statistical models suggested by other previous published techniques [22,
25]. Our MRI method overcomes the differences in fat storage between men and women
which makes other single slice methods unreliable [54]. MRI methods are also superior to CT
scanning, as there is no harmful radiation, and multiple slices can be collected in just a few
breath holds. While the link between calprotectin and VAT was a post hoc discovery and
though plausible mechanistically, needs repeating to ensure it is not due to chance, the method
shows promise and can be applied to other diseases such as Crohn’s, where the effects of
abdominal adiposity can be investigated.
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